pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include:
- 6 products completed CADTH review, for a total of 15 files under consideration;
- 9 products initiated pCPA negotiations, for a total of 49 active negotiations;
- 4 negotiations completed for a total of 257 completed negotiations;
- 3 negotiations closed, for a total of 40 closed negotiations; and
- 1 file closed without negotiations, for a total of 66 declined negotiations.
Files Under pCPA Consideration
6 new drug products received a CDEC recommendation or pERC notification to implement in June 2019, for a total of approximately 15* products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Xalkori | Crizotinib | Pfizer | ROS1-positive advanced Non-Small Cell Lung Cancer | Conditional |
| Venclexta + rituximab | Venetoclax + Rituximab | AbbVie | Chronic Lymphocytic leukemia (CLL) | Conditional |
| Keytruda | Pembrolizumab | Merck | Non-Squamous NSCLC | Conditional |
| Sublocade | Buprenorphine | Indivior | Opioid Use Disorder | Conditional |
| Cystadrops | Cysteamine | Recordati Rare Diseases | Corneal cystine crystal deposits | Conditional |
| Xermelo | Telotristat | Ipsen | Carcinoid Syndrome |
Do not reimburse
|
* Negotiations for Cystadrops and Venclexta + rituximab were initiated the same month these files received CADTH recommendations and thus are not included in the count of products under pCPA Consideration
Signals Decoded:
Over the past 12 months, the average time files have spent under pCPA Consideration has decreased from 5.4 months (Jul 2018) to 1.5 months (Jun 2019). At present, the longest any file has been under pCPA consideration is 4 months – Xeljanz for Ulcerative Colitis.
Negotiation Initiation
The pCPA initiated 9 new negotiations since the last update, for a total of 49 active negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Initiation Time* |
|---|---|---|---|---|---|
| Cabometyx | Cabozantinib | Ipsen | Renal Cell Carcinoma | 7 Mar 19 | 100 days |
| Cystadrops | Cysteamine | Recordati Rare Diseases | Corneal cystine crystal deposits | 18 Jun 19 | 0 days |
| Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | Merck Canada | HIV infection | 14 May 19 | 32 days |
| Folotyn | Pralatrexate | Servier | Peripheral T-Cell Lymphoma | 22 Apr 19 | 54 days |
| Opdivo | Nivolumab | Bristol Myers Squibb | Melanoma Adjuvant Therapy | 22 Mar 19 | 85 days |
| Pifeltro | Doravirine | Merck Canada | HIV-1 | 14 May 19 | 32 days |
| Skyrizi | Risankizumab | AbbVie | Plaque Psoriasis | 28 May 19 | 18 days |
| Tafinlar/Mekinist | Dabrafenib/trametinib | Novartis | Melanoma Adjuvant Therapy | 21 May 19 | 25 days |
| Venclexta/Rituximab | Venetoclax/rituximab | AbbVie | Chronic lymphocytic leukemia | 17 Jun 19 | 0 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Completed
| Brand Name | Generic Name | Manufacturer | Indication | Initiation | Duration* |
|---|---|---|---|---|---|
| Biktarvy | bictegravir/emtricitabine/tenofovir alafenamide | Gilead Sciences | HIV | Feb 2019 | 120 days |
| Brilinta | Ticagrelor | AstraZeneca | Secondary prevention, atherothrombotic events | May 2019 | 31 days |
| Ella | Ulipristal acetate | Laboratoire HRA Pharma | Prevention of pregnancy | Feb 2019 | 120 days |
| Spinraza | Nusinersen | Biogen | Spinal Muscular Atrophy | Apr 2019 | 61 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Closed
| Brand Name | Generic Name | Manufacturer | Indication | Initiation | Duration* |
|---|---|---|---|---|---|
| Onivyde | Irinotecan lipsome | Servier Canada Inc. | Metastatic pancreatic cancer | Jan 2019 | 151 days |
| Tremfya | Guselkumab | Janssen | Moderate to severe plaque psoriasis | Oct 2018 | 243 days |
| Xolair | Omalizumab | Novartis | Severe persistent asthma | Oct 2016 | 973 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
June saw the completion of a second negotiation for both Spinraza and Brilinta which is the latest file to be re-initiated and successfully negotiated after being previously closed without an agreement. Three files were closed without agreements including Xolair which had been under active negotiations for severe persistent asthma for over two-and-a-half years.
Declined Negotiations
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Decision* |
|---|---|---|---|---|---|
| Jublia | Efinaconazole | Valeant Canada | Onychomycosis | 23 May 19 | 23 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
